Tag - XENE

Developments

Three finalists announced for Bloom Burton Award

The finalists for the 2023 Bloom Burton Award are: Stephen Dilly, former president and CEO, Sierra Oncology Ian Mortimer, president and CEO, Xenon Pharmaceuticals Dave Wessinger, co-founder and CEO, and Mike Wessinger...

May 4, 2023

Markets

Stifel ups Xenon Pharma PT to $31 from $23

Stifel raised its price target for Xenon Pharmaceuticals (NASDAQ:XENE) to $31 from $23, ahead of Phase 2b focal seizure data expected in the third quarter this year. The stock closed at $17.97 on April 23. “From our...

April 26, 2021

Markets

WB starts Xenon Pharma at OP; estimated fair value $27

William Blair initiated coverage of Xenon Pharmaceuticals (NASDAQ:XENE) with an “outperform” rating and estimated fair value of $27. The stock closed at $13.49 on Jan. 7. Xenon is focused on the development of selective...

January 8, 2020

Feature

Xenon still committed to TV-45070 for neuropathic pain

By Len Zehr Xenon Pharmaceuticals (NASDAQ:XENE) and its development and commercialization partner, Teva Pharmaceutical Industries (NYSE, TASE:TEVA), remain fully committed to the development of TV-45070 for neuropathic...

July 21, 2015

Tag - XENE

Three finalists announced for Bloom Burton Award

Stifel ups Xenon Pharma PT to $31 from $23

WB starts Xenon Pharma at OP; estimated fair value $27

Xenon still committed to TV-45070 for neuropathic pain

General

More